NOVARTIS logo.jpg
Novartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19
April 28, 2020 01:00 ET | Novartis International AG
  Q1 2020 net sales from continuing operations1 grew 13% (cc2, +11% USD) with double digit growth (cc) in Innovative Medicines and Sandoz: Key growth drivers include Entresto USD 569 million (+62%...
NOVARTIS logo.jpg
Novartis conserve une forte performance opérationnelle au 1er trimestre, confirme à ce stade les prévisions pour 2020 et fournit de grands efforts pour contribuer à la réponse mondiale au Covid-19
April 28, 2020 01:00 ET | Novartis International AG
Au 1er trimestre 2020, chiffre d’affaires net des activités poursuivies1 en hausse de 13% (tcc2, +11% USD) avec une croissance à deux chiffres (tcc) d’Innovative Medicines et de Sandoz: Les...
NOVARTIS logo.jpg
Novartis setzt im 1. Quartal die starke operative Performance fort, bestätigt derzeit die Prognose 2020 und fördert verschiedenste Aktivitäten, um globale Massnahmen gegen COVID-19 zu unterstützen
April 28, 2020 01:00 ET | Novartis International AG
Der Nettoumsatz der fortzuführenden Geschäftsbereiche1 steigt im ersten Quartal 2020 um 13% (kWk2, +11% USD) mit zweistelligen Zuwächsen (kWk) bei Innovative Medicines und Sandoz: Zu den...
NOVARTIS logo.jpg
Novartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host disease
April 22, 2020 17:01 ET | Novartis International AG
Data from Phase III REACH2 study, published in The New England Journal of Medicine, demonstrate Jakavi can improve outcomes for patients with acute graft-versus-host disease (GvHD) who do not respond...
NOVARTIS logo.jpg
Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
April 22, 2020 01:15 ET | Novartis International AG
If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults...
NOVARTIS logo.jpg
Novartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)
April 21, 2020 01:15 ET | Novartis International AG
New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed...
NOVARTIS logo.jpg
Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients
April 20, 2020 01:32 ET | Novartis International AG
Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease Trial...
NOVARTIS logo.jpg
Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig® as a preventive treatment across the full spectrum of migraine
April 16, 2020 01:15 ET | Novartis International AG
Real-world evidence supports benefits seen in Aimovig clinical trials  Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine Post-hoc and...
NOVARTIS logo.jpg
Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program
April 02, 2020 17:05 ET | Novartis International AG
New clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm  Cytokine storm is a type of severe immune overreaction that can result from coronavirus...
NOVARTIS logo.jpg
Novartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to Aurobindo
April 01, 2020 22:00 ET | Novartis International AG
Basel, April 2, 2020 – Novartis today announced the mutual agreement with Aurobindo Pharma USA Inc. to terminate the agreement to sell the Sandoz US generic oral solids and dermatology businesses to...